Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

Eiermann, W.; Pienkowski, T.; Crown, J.; Sadeghi, S.; Chan, Arlene; Saleh, M.; Sehdev, S.; Provencher, L.; Semiglazov, V.; Press, M.; Sauter, G.; Lindsay, M.; Riva, A.; Buyse, M.; Drevot, P.; Taupin, H.; Mackey, J.

Access Status

Fulltext not available

Authors

Eiermann, W.

Pienkowski, T.

Crown, J.

Sadeghi, S.

Chan, Arlene

Saleh, M.

Sehdev, S.

Provencher, L.

Semiglazov, V.

Press, M.

Sauter, G.

Lindsay, M.

Riva, A.

Buyse, M.

Drevot, P.

Taupin, H.

Mackey, J.

Date

2011

Type

Journal Article

Metadata

Show full item record

Citation

Eiermann, W. and Pienkowski, T. and Crown, J. and Sadeghi, S. and Chan, A. and Saleh, M. and Sehdev, S. et al. 2011. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. Journal of Clinical Oncology. 29 (29): pp. 3877-3884.

Source Title

Journal of Clinical Oncology